Straits Times Index
3,265.95 +1.42 (+0.04%) S&P 500
5,214.08 +26.41 (+0.51%) Dow
39,387.76 +331.37 (+0.85%) Nasdaq
16,346.26 +43.46 (+0.27%) Bitcoin USD
62,552.53 +1,053.36 (+1.71%) CMC Crypto 200
1,343.88 +43.78 (+3.37%)
TARA May 2024 5.000 call
| Previous close | 0.0500 |
| Open | 0.0500 |
| Bid | 0.0000 |
| Ask | 0.1000 |
| Strike | 5.00 |
| Expiry date | 2024-05-17 |
| Day's range | 0.0500 - 0.1000 |
| Contract range | N/A |
| Volume | |
| Open interest | 381 |
GlobeNewswireProtara Therapeutics Announces First Quarter 2024 Financial Results and Provides Business Update
Reported positive data from three-month evaluable CIS patients treated across ongoing TARA-002 clinical program in NMIBCPreliminary data from six-month evaluable patients in ADVANCED-2 trial of TARA-002 in NMIBC expected in 2H 2024Reached alignment with FDA on registrational path forward for IV Choline Chloride in patients dependent on parenteral nutritionCurrent cash resources, together with approximately $45.0 million in gross proceeds from April 2024 private placement, expected to fund operat
- GlobeNewswire
Protara Therapeutics Announces Oversubscribed $45 Million Private Placement Financing
Anticipated net proceeds, along with existing cash and cash equivalents, expected to extend cash runway into 2026NEW YORK, April 05, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that it has entered into a subscription agreement for the sale of an aggregate of 9,143,380 shares of its common stock (Shares) or, for certain purchasers, pre-funded warrants
- GlobeNewswire
Protara Therapeutics Announces Alignment with FDA on Registrational Path Forward for IV Choline Chloride in Patients Dependent on Parenteral Nutrition
New development pathway significantly expands addressable patient population for IV Choline ChlorideIV Choline Chloride has the potential to become the first FDA-approved IV formulation of choline for the 40,000 PN patients in the U.S.Approximately 80% of PN patients are choline deficient, which can lead to liver damage and hepatic failure; ASPEN recommends choline replacement for PN patientsCompany expects to start registrational trial to support FDA approval of IV Choline Chloride for PN patie
